MedPath

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

Phase 2
Withdrawn
Conditions
Squamous Cell Carcinoma of Head and Neck
Head and Neck Cancer
Interventions
Biological: enoblituzumab
Biological: MGA012
Biological: MGD013
Registration Number
NCT04129320
Lead Sponsor
MacroGenics
Brief Summary

This is an open-label study designed to evaluate safety and efficacy of enoblituzumab in combination with MGA012 or MGD013 in first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Detailed Description

The study will initially be conducted in 2 modules, Module X (enoblituzumab plus MGA012) and Module Y (enoblituzumab plus MGD013). Enrollment into Modules X and Y, with approximately 30 patients each, will occur independently in a non-randomized fashion. Data from these modules will determine if further evaluation will occur in randomized Module A (Phase 2) and randomized Module B (Phase 3).

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Histologically proven, recurrent or metastatic SCCHN not curable by local therapy
  • No prior systemic therapy for SCCHN in the recurrent or metastatic setting (with the exception of systemic therapy completed > 6 months prior of given as part of multimodal treatment for locally advanced disease)
  • Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx
  • At least one radiographically measurable lesion
  • HPV test results available (positive and negative eligible)
  • ECOG Performance status of 0 or 1
  • Adequate end organ function
  • Positive PD-L1 expression level (CPS ≥ 1%)
Exclusion Criteria
  • Disease suitable for local therapy administered with curative intent
  • Progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced SCCHN
  • Radiation or other non-systemic therapy within 2 weeks of first dose of study drug
  • Diagnosis of immunodeficiency, or use of immunosuppresive therapy within 14 days of first dose of study drug

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental Arm 1enoblituzumabEnoblituzumab plus MGA012
Experimental Arm 1MGA012Enoblituzumab plus MGA012
Experimental Arm 2enoblituzumabEnoblituzumab plus MGD013
Experimental Arm 2MGD013Enoblituzumab plus MGD013
Primary Outcome Measures
NameTimeMethod
Incidence of Adverse Events as assessed by CTCAE v 4.03 (Modules X and Y)Up to 30 days after last dose of study drug

Evaluation of adverse events and serious adverse events

Overall Response Rate (Modules X and Y)2 years

Proportion of patients with best overall response of complete response (CR) plus partial response (PR) per RECIST 1.1

Secondary Outcome Measures
NameTimeMethod
Duration of Response - (Modules X and Y)2 years

Time from the date of initial response to the date of first documented progression or death from any cause, whichever occurs first

Ctrough (Module X)2 years

Trough serum concentration of enoblituzumab and MGA012

Immunogenicity (Module X)2 years

Percentage of patients developing anti-drug antibodies to enoblituzumab and/or MGA012

Ctrough (Module Y)2 years

Trough serum concentration of enoblituzumab and MGD013

Progression-free Survival - (Modules X and Y)2 years

Time from start of study treatment to the first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first.

Disease Control Rate - (Modules X and Y)2 years

Percentage of patients who experienced response of CR, PR or stable disease for at least 3 months from start of study treatment

Immunogenicity (Module Y)2 years

Percentage of patients developing anti-drug antibodies to enoblituzumab and/or MGD013

Cmax (Module Y)2 years

Maximum serum concentration of enoblituzumab and MGD013

Cmax (Module X)2 years

Maximum serum concentration of enoblituzumab and MGA012

© Copyright 2025. All Rights Reserved by MedPath